Starling Oncology, Inc. (STLNW) Operating margin 2020–2025
Starling Oncology, Inc. (STLNW) operating margin by fiscal year — reported operating income divided by reported revenue.
-7.2%FY2025 · since FY2020: -4.4% → -7.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -7.2% | +8.1 pp |
| FY2024 | -15.3% | +8.5 pp |
| FY2023 | -23.8% | +8.7 pp |
| FY2022 | -32.5% | -9.9 pp |
| FY2021 | -22.6% | -18.2 pp |
| FY2020 | -4.4% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More STLNW financial trends
STLNW RevenueSTLNW Net incomeSTLNW Net marginSTLNW Gross profitSTLNW Gross marginSTLNW Operating incomeSTLNW Operating cash flowSTLNW Free cash flowSTLNW Capital expendituresSTLNW Return on equitySTLNW Stock buybacksSTLNW Dividends paidSTLNW Total assetsSTLNW Total liabilitiesSTLNW Shareholders’ equitySTLNW overview →